Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Anti-PD(L)1
Bladder cancer
Immune Checkpoint Inhibitors
Immunotherapy
Urinary tract cancer
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
29
05
2023
revised:
14
06
2023
accepted:
15
06
2023
medline:
2
10
2023
pubmed:
7
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Platinum-based chemotherapy (PBC) followed by avelumab switch maintenance in nonprogressors is standard first line (1L) treatment for advanced urothelial carcinoma (aUC). We describe clinical features and outcomes in a "real-world' cohort treated with avelumab maintenance for aUC. This was a retrospective cohort study of patients (pts) who received 1L switch maintenance avelumab after no progression on PBC for aUC. We calculated progression-free survival (PFS) and overall survival (OS) from initiation of maintenance avelumab. We also described OS and PFS for specific subsets using Cox regression and observed response rate (ORR). A total of 108 pts with aUC from 14 sites treated with maintenance avelumab were included. There was a median of 6 weeks Results seem relatively consistent with findings from JAVELIN Bladder100 trial and recent "real world" studies. Prior response to platinum-based chemotherapy, ECOG PS 0, and absence of liver metastases were favorable prognostic factors. Limitations include the retrospective design, lack of randomization and central scan review, and possible selection/confounding biases.
Sections du résumé
BACKGROUND
Platinum-based chemotherapy (PBC) followed by avelumab switch maintenance in nonprogressors is standard first line (1L) treatment for advanced urothelial carcinoma (aUC). We describe clinical features and outcomes in a "real-world' cohort treated with avelumab maintenance for aUC.
MATERIALS AND METHODS
This was a retrospective cohort study of patients (pts) who received 1L switch maintenance avelumab after no progression on PBC for aUC. We calculated progression-free survival (PFS) and overall survival (OS) from initiation of maintenance avelumab. We also described OS and PFS for specific subsets using Cox regression and observed response rate (ORR).
RESULTS
A total of 108 pts with aUC from 14 sites treated with maintenance avelumab were included. There was a median of 6 weeks
CONCLUSIONS
Results seem relatively consistent with findings from JAVELIN Bladder100 trial and recent "real world" studies. Prior response to platinum-based chemotherapy, ECOG PS 0, and absence of liver metastases were favorable prognostic factors. Limitations include the retrospective design, lack of randomization and central scan review, and possible selection/confounding biases.
Identifiants
pubmed: 37414620
pii: S1558-7673(23)00147-7
doi: 10.1016/j.clgc.2023.06.008
pii:
doi:
Substances chimiques
avelumab
KXG2PJ551I
Antibodies, Monoclonal
0
Platinum
49DFR088MY
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-593Subventions
Organisme : NCI NIH HHS
ID : T32 CA094880
Pays : United States
Organisme : Wellcome Trust
ID : PS3416
Pays : United Kingdom
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.